Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

Leukemia

Volumn 30, Issue 10, 2016, Pages 2080-2083

  Othus, M ^a   Wood, B L ^b   Stirewalt, D L ^a,b   Estey, E H ^a,b   Petersdorf, S H ^a,b   Appelbaum, F R ^a,b   Erba, H P ^c   Walter, R B ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Heerskink School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMTUZUMAB OZOGAMICIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT DISEASE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CELL LINEAGE; DE NOVO ACUTE MYELOID LEUKEMIA; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LETTER; LEUKOCYTE COUNT; MEDICAL INFORMATION; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RELAPSE; THROMBOCYTE COUNT; ACUTE MYELOID LEUKEMIA; ADULT; PATHOLOGY; RECURRENT DISEASE; SURVIVAL ANALYSIS;

ADULT; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; RECURRENCE; SURVIVAL ANALYSIS;

EID: 84968677428     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.120     Document Type: Letter

References (15)

1. Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ et al. Resistance prediction in AML: Analysis of 4601 patients from MRC/NCRI, HOVON/ SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2015; 29: 312-320.
2. Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia 2015; 29: 2104-2107.
3. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854-4860.
4. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Time to move toward a minimal residual disease-based definition of complete remission J Clin Oncol 2016; 34: 329-336.
5. Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB et al. Pre-and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 2016; 30: 1456-1464.
6. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417-4423.
7. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42 A study. J Clin Oncol 2013; 31: 3889-3897.
8. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123-4131.
9. Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 2015; 33: 1258-1264.
10. Elliott MA, Litzow MR, Letendre LL, Wolf RC, Hanson CA, Tefferi A et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007; 110: 4172-4174.
11. Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: A GOELAMS study. Leukemia 2009; 23: 350-357.
12. Vainstein V, Buckley SA, Shukron O, Estey EH, Abkowitz JL, Wood BL et al. Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 2014; 28: 713-716.
13. Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R et al. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the '3+7' induction regimen for acute myeloid leukemia. Am J Hematol 2015; 90: 1159-1164.
14. Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944-4951.
15. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016; 374: 422-433.